Virtus ETF Advisers LLC Allogene Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 36,285 shares of ALLO stock, worth $75,109. This represents 0.05% of its overall portfolio holdings.

Number of Shares

36,285

Previous 35,640 1.81%

Holding current value

$75,109

Previous $83,000 21.69%

% of portfolio

0.05%

Previous 0.04%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $1,341 - $2,257	645 Added 1.81%	36,285 $101,000
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $8,190 - $16,087	3,673 Added 11.49%	35,640 $83,000
Q1 2024 May 15, 2024	SELL	$2.92 - $5.63 $6,412 - $12,363	-2,196 Reduced 6.43%	31,967 $142,000
Q4 2023 Feb 15, 2024	BUY	$2.28 - $3.5 $32,667 - $50,148	14,328 Added 72.24%	34,163 $109,000
Q3 2023 Nov 07, 2023	SELL	$3.17 - $5.96 $6,270 - $11,788	-1,978 Reduced 9.07%	19,835 $62,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $39,601 - $58,921	8,742 Added 66.88%	21,813 $108,000
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $24,727 - $41,263	-5,026 Reduced 27.77%	13,071 $64,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $37,288 - $73,714	6,635 Added 57.89%	18,097 $113,000
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $815 - $1,365	79 Added 0.69%	11,462 $124,000
Q2 2022 Aug 12, 2022	BUY	$6.78 - $12.28 $3,627 - $6,569	535 Added 4.93%	11,383 $130,000
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $4,888 - $9,770	-639 Reduced 5.56%	10,848 $99,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $40,808 - $76,208	3,108 Added 37.09%	11,487 $171,000
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $9,202 - $12,106	-438 Reduced 4.97%	8,379 $215,000
Q2 2021 Aug 10, 2021	SELL	$23.49 - $35.8 $44,724 - $68,163	-1,904 Reduced 17.76%	8,817 $230,000
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $4,771 - $7,218	185 Added 1.76%	10,721 $378,000
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $73,827 - $127,091	2,925 Added 38.43%	10,536 $266,000
Q3 2020 Nov 13, 2020	SELL	$32.38 - $44.96 $33,642 - $46,713	-1,039 Reduced 12.01%	7,611 $287,000
Q2 2020 Aug 05, 2020	SELL	$18.39 - $54.04 $85,127 - $250,151	-4,629 Reduced 34.86%	8,650 $370,000
Q1 2020 May 14, 2020	SELL	$18.22 - $28.25 $35,255 - $54,663	-1,935 Reduced 12.72%	13,279 $258,000
Q4 2019 Feb 13, 2020	BUY	$24.82 - $31.4 $140,530 - $177,786	5,662 Added 59.28%	15,214 $395,000
Q3 2019 Nov 12, 2019	SELL	$26.11 - $32.99 $13,890 - $17,550	-532 Reduced 5.28%	9,552 $260,000
Q2 2019 Aug 13, 2019	BUY	$25.56 - $31.09 $257,747 - $313,511	10,084 New	10,084 $271,000

Others Institutions Holding ALLO

# of Institutions

162

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $298M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Allogene Therapeutics, Inc. Transaction History